Rigel Pharmaceuticals published final data from its Phase 1/2 ARROW trial of pralsetinib (Gavreto) in metastatic RET fusion-positive NSCLC in the Journal of Clinical Oncology. The update adds 42 months of follow-up to previously reported results. In patients with measurable disease (n=259), the overall response rate was 70%, including 7% complete responses and 63% partial responses, with no new safety signals reported and no hypersensitivity reactions in patients receiving prior immunotherapies. Company and investigator commentary emphasized durable benefit, including patients with baseline measurable CNS metastases, reinforcing pralsetinib’s positioning as an early-biomarker-driven option.